The Cerebral scandal brings ADHD overprescription into the spotlight
A telehealth company's downfall sheds light on the overprescription of stimulants to ADHD patients More
How mental health apps can accelerate the psychiatric prescribing cascade
Mental health apps designed to improve access to care may be driving overdiagnosis and overmedication, a recent investigation finds. More
When meds taken “as prescribed” still cause harm
A group of advocates has been sounding the alarm about the risk of side effects from benzodiazepines, even when taken as directed. An upcoming documentary tells their stories. More
How electronic tools can help deprescribe in the hospital
The Medsafer study shows how clinical decision tools can help doctors deprescribe more in the hospital. More
How we achieve equal access to pharmaceutical treatment
Research shows that people of color are more likely to experience underuse of needed medications. How do we achieve equity in access to affordable, high-quality medications? More
Why are dentists still overprescribing opioids?
Despite the known risks, dentists still prescribe too many opioids to young adults and teens. How can we reverse this pattern? More
Stop taking aspirin for primary prevention, task force says
Does an aspirin a day keep the doctor away? It used to be the conventional wisdom that taking low-dose aspirin helped prevent a first heart attack or stroke. However, the evidence isn't there to back up this practice. More
Most Medicare patients with dementia wouldn’t have been eligible for Aduhelm trials
The FDA approved Alzheimer's drug Aduhelm for all people with mild dementia -- but most of this population is at an increased risk of side effects from the drug. More
New Alzheimer’s drug may burden state budgets
State budgets are already being squeezed by rising health care costs, leaving less for public health and social spending. How will the cost of new Alzheimer's drug Aduhelm impact Medicaid costs and state budgets? More
FDA approval of new Alzheimer’s drug sets a dangerous precedent
The FDA's approval of a new Alzheimer's treatment has significant implications for future drug trials, health system costs, patient safety, and conflicts of interest. More